An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors
- PMID: 28491011
- PMCID: PMC5424371
- DOI: 10.1186/s12014-017-9152-2
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors
Abstract
Background: Epithelial ovarian carcinomas encompass a heterogeneous group of diseases with a poor 5-year survival rate. Serous carcinoma is the most common type. Most FDA-approved serum tumor markers are glycoproteins. These glycoproteins on cell surface or shed into the bloodstream could serve as therapeutic targets as well as surrogates of tumor. In addition to glycoprotein expressions, the analysis of protein glycosylation occupancy could be important for the understanding of cancer biology as well as the identification of potential glycoprotein changes in cancer. In this study, we used an integrated proteomics and glycoproteomics approach to analyze global glycoprotein abundance and glycosylation occupancy for proteins from high-grade ovarian serous carcinoma (HGSC) and serous cystadenoma, a benign epithelial ovarian tumor, by using LC-MS/MS-based technique.
Methods: Fresh-frozen ovarian HGSC tissues and benign serous cystadenoma cases were quantitatively analyzed using isobaric tags for relative and absolute quantitation for both global and glycoproteomic analyses by two dimensional fractionation followed by LC-MS/MS analysis using a Orbitrap Velos mass spectrometer.
Results: Proteins and N-linked glycosite-containing peptides were identified and quantified using the integrated global proteomic and glycoproteomic approach. Among the identified N-linked glycosite-containing peptides, the relative abundances of glycosite-containing peptide and the glycoprotein levels were compared using glycoproteomic and proteomic data. The glycosite-containing peptides with unique changes in glycosylation occupancies rather than the protein expression levels were identified.
Conclusion: In this study, we presented an integrated proteomics and glycoproteomics approach to identify changes of glycoproteins in protein expression and glycosylation occupancy in HGSC and serous cystadenoma and determined the changes of glycosylation occupancy that are associated with malignant and benign tumor tissues. Specific changes in glycoprotein expression or glycosylation occupancy have the potential to be used in the discrimination between benign and malignant epithelial ovarian tumors and to improve our understanding of ovarian cancer biology.
Keywords: Glycoproteomics; Ovarian high-grade serous carcinoma; Proteomics.
Figures
Similar articles
-
Integrated proteomic and N-glycoproteomic analyses of doxorubicin sensitive and resistant ovarian cancer cells reveal glycoprotein alteration in protein abundance and glycosylation.Oncotarget. 2017 Feb 21;8(8):13413-13427. doi: 10.18632/oncotarget.14542. Oncotarget. 2017. PMID: 28077793 Free PMC article.
-
Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation.Mol Cell Proteomics. 2015 Oct;14(10):2753-63. doi: 10.1074/mcp.M115.047928. Epub 2015 Aug 9. Mol Cell Proteomics. 2015. PMID: 26256267 Free PMC article.
-
Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.Cell Rep. 2020 Oct 20;33(3):108276. doi: 10.1016/j.celrep.2020.108276. Cell Rep. 2020. PMID: 33086064 Free PMC article.
-
A case for protein-level and site-level specificity in glycoproteomic studies of disease.Glycoconj J. 2016 Jun;33(3):377-85. doi: 10.1007/s10719-016-9663-5. Epub 2016 Mar 23. Glycoconj J. 2016. PMID: 27007620 Review.
-
Cell Origins of High-Grade Serous Ovarian Cancer.Cancers (Basel). 2018 Nov 12;10(11):433. doi: 10.3390/cancers10110433. Cancers (Basel). 2018. PMID: 30424539 Free PMC article. Review.
Cited by
-
Recent Advances in Glycoproteomic Analysis by Mass Spectrometry.Anal Chem. 2020 Jan 7;92(1):267-291. doi: 10.1021/acs.analchem.9b04651. Epub 2019 Nov 4. Anal Chem. 2020. PMID: 31626732 Free PMC article. Review. No abstract available.
-
Global and site-specific analysis of protein glycosylation in complex biological systems with Mass Spectrometry.Mass Spectrom Rev. 2019 Aug;38(4-5):356-379. doi: 10.1002/mas.21586. Epub 2019 Jan 3. Mass Spectrom Rev. 2019. PMID: 30605224 Free PMC article. Review.
-
Orthogonal Proteomic Platforms and Their Implications for the Stable Classification of High-Grade Serous Ovarian Cancer Subtypes.iScience. 2020 Jun 26;23(6):101079. doi: 10.1016/j.isci.2020.101079. Epub 2020 Apr 18. iScience. 2020. PMID: 32534439 Free PMC article.
-
Recent Advances in the Mass Spectrometry Methods for Glycomics and Cancer.Anal Chem. 2018 Jan 2;90(1):208-224. doi: 10.1021/acs.analchem.7b04202. Epub 2017 Oct 31. Anal Chem. 2018. PMID: 29049885 Free PMC article. Review.
-
Mass spectrometry-based proteomics as an emerging tool in clinical laboratories.Clin Proteomics. 2023 Aug 26;20(1):32. doi: 10.1186/s12014-023-09424-x. Clin Proteomics. 2023. PMID: 37633929 Free PMC article. Review.
References
-
- Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO classification of tumours of female reproductive organs. 4. Lyon: IARC Press; 2014.
-
- Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;389(10022):945–956. doi: 10.1016/S0140-6736(15)01224-6. - DOI - PMC - PubMed
-
- Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Jr, Gaarenstroom KN, Sturgeon CM, Bonfrer JM, Petersen PH, Troonen H, CarloTorre G, Kanty Kulpa J, Tuxen MK, Molina R. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the european group on tumor markers. Int J Gynecol Cancer. 2016;26:43–51. doi: 10.1097/IGC.0000000000000586. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources